Finding broadly protective antibodies for Crimean‑Congo hemorrhagic fever
Official title: Isolation of broadly protective monoclonal antibodies for Crimean Congo Hemorrhagic Fever
Funded at University of Maryland Baltimore · NIH-11143287 · Data updated 2026-11-12
Researchers are collecting blood from people who recovered from Crimean‑Congo hemorrhagic fever to find antibodies that could protect others from the virus.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Maryland Baltimore NIH-funded |
| Lab location | 1 site (Baltimore, United States) |
| Project start | July 23, 2024 |
| Project end | June 30, 2029 |
| Funding year | 2025 |
| Award (this year) | $611,747 |
| NIH project number | 5R01AI180125-02 |
| Project ID | NIH-11143287 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates are people who previously had and recovered from laboratory‑confirmed CCHF and are willing to provide blood samples, particularly survivors in the study area (Turkey).
✕Less likely to help
People who have never had CCHF, are currently infected, or are unable/unwilling to give blood are unlikely to be eligible or receive direct benefit from participation.
What this research studies
If you join, researchers will build a group of about 120 people who recovered from CCHF and collect blood samples to look for protective antibodies. They will isolate a large panel of antibodies from those samples and pick the most promising candidates for further study. The best antibodies will be tested in lab and mouse models to see if they protect against different virus strains. The team will also map exactly where the leading antibodies bind on the virus to help guide future treatments or vaccines.
Why it matters
Potential benefit: This work could lead to antibody-based treatments or help design vaccines that prevent or treat CCHF in the future.
How similar studies have gone: Similar approaches have identified protective monoclonal antibodies in animals and some human antibodies have been isolated, but broadly cross‑protective human antibodies against multiple CCHFV strains remain limited.
Where this research is happening
-
University of Maryland Baltimore
Baltimore, United States Active
Researchers
- Principal investigator: Sajadi, Mohammad Mohseni — University of Maryland Baltimore
- Study coordinator: Sajadi, Mohammad Mohseni
Related research
Other NIH-funded projects on the same topics.
-
Broad antiviral drugs that target coronaviruses and other viruses
A research program aims to identify small molecules that can block multiple viruses, focusing first on coronaviruses, to help create drugs that can treat future outbreaks.
-
Finding broadly protective antibodies against Crimean-Congo Hemorrhagic Fever
Researchers will study blood from people who survived CCHF to find human antibodies that protect against multiple virus variants, with early tests in animal models to check their breadth.
-
Antivirals for hemorrhagic fever viruses like LASV, SFTSV, and EBOV
A multi-institutional effort to find and validate antiviral compounds that block key viral proteins from LASV, SFTSV, and EBOV to help people at risk from serious hemorrhagic fevers.
-
A New Model for Valley Fever: Studying Coccidioides Infection with Volatile Clues in Wax Moths
Researchers are testing a new, cheaper model using wax moths to study Valley Fever caused by Coccidioides, with the goal of understanding how the infection behaves and how it could be diagnosed or treated.
-
Halogen-modified nucleoside analogs to fight yellow fever virus
Aims to develop new oral medicines that could prevent or treat yellow fever by using specially modified building blocks that stop the virus from growing.
-
Understanding Guanarito virus and building countermeasures for Venezuelan hemorrhagic fever
This project studies how Guanarito virus causes disease and aims to develop vaccines or treatments to protect people in areas where Venezuelan hemorrhagic fever occurs.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.